Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.59 |
| ▸ | TSHR | P16473 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952460 | 0.93 | CLK4 (0.52) | CLK4CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL379615 | 0.89 | CLK4 (0.53) | CLK4CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL379599 | 0.87 | ALDH1A1 (0.63) | CLK4CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL379675 | 0.84 | TUBB4A (0.45) | CLK4CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL379865 | 0.82 | ESR1 (0.55) | CYP1A2CYP2D6CYP2C19CYP3A4HSD17B10 | |
| SCHEMBL379757 | 0.79 | CCNC (0.47) | MAPK1DYRK1ATP53HPGDMEN1 | |
| SCHEMBL379602 | 0.79 | PDE11A (0.47) | HSD17B10TSHRALDH1A1MAPK1LMNA | |
| SCHEMBL4946829 | 0.78 | PDE11A (0.49) | HSD17B10TSHRALDH1A1MAPK1LMNA | |
| SCHEMBL379868 | 0.78 | TUBB4A (0.45) | CLK4ALDH1A1LMNADYRK1AMAPT | |
| SCHEMBL4954711 | 0.78 | CLK4 (0.49) | CLK4CYP1A2CYP2D6CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | claimed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | claimed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | claimed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | claimed |
| US-9216992-B2 | Thieno[3,2-c]pyridine potassium channel inhibitors | XENTION LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | disclosed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161672-A1 | Compounds | KCNJ2, KCNT1, KCNT2 | CLK4 3601/4885CYP1A2 406/4885CYP2D6 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.